Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast
- 1 March 2002
- Vol. 121 (3) , 732-738
- https://doi.org/10.1378/chest.121.3.732
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trialsThorax, 2000
- Aspirin-induced asthma: Advances in pathogenesis and management☆☆☆Journal of Allergy and Clinical Immunology, 1999
- Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthmaJournal of Allergy and Clinical Immunology, 1998
- Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced BronchoconstrictionNew England Journal of Medicine, 1998
- The Role and Contribution of Leukotrienes in AsthmaAnnals of Allergy, Asthma & Immunology, 1998
- Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroidsThorax, 1997
- Leukotriene E4 and granulocytic infiltration into asthmatic airwaysThe Lancet, 1993
- Asthma, inflammation, eosinophils and bronchial hyperresponsivenessClinical and Experimental Allergy, 1992
- Use of induced sputum cell counts to investigate airway inflammation in asthma.Thorax, 1992
- Leukotrienes are potent constrictors of human bronchiNature, 1980